additional modality for the extraction of 'complex' stones; fully covered self-expanding metal stent (fcSEMS) insertion alongside the 'complex' stone (Hartery et al, 2017) over a 3 year period at a single centre.

Methods Prospective study whereby patients with failed stone extraction by conventional techniques (sphincterotomy, sphincteroplasty - Boston CRE Balloon 10–20 mm, lithotripsy - Olympus LithoCrushV, plastic stenting - 2 double pigtail stents 7–10Fr) underwent temporary fcSEMS insertion (Boston Wallflex 10 mm × 6 cm or 8 cm) alongside the complex stone for at least 4 weeks. Follow up ERCP was arranged and the fcSEMS was removed and stone extraction reattempted. Stones were classified as Cotton Grade 2 (<10 mm) or 3 (≥10 mm) with both cannulation and extraction rates assessed as ITT and per protocol.

Results Over a 36 month period 311 ERCPs were performed on 271 patients with CBD stones (238 Cotton Grade 2, 81 Cotton Grade 3). Cannulation at 1st ERCP was 95.2% (258/271). Stone clearance at 1st ERCP was 82% overall (221/271); 86% (179/209) for Cotton Grade 2 and 68% (42/62) for Cotton Grade 3. Stone clearance at 1st or 2nd ERCP was 91% overall (247/271); 94% for Cotton Grade 2 (196/209) and 82% for Cotton Grade 3 (51/62). Using conventional techniques 24 patients did not achieve CBD clearance of which 13 did not have a repeat ERCP (non-attendance, frailty or death).

A fcSEMS was inserted in 11 patients (stone size 9–33 mm, age range 59–87 years). In 10 patients CBD clearance was achieved after a single SEMS insertion. With one patient a second fcSEMS insertion was required for a particularly large stone (35 mm) which did not fully fragment after the first procedure. Pancreatitis, perforation and cholangitis were not experienced in any of the patients in which a fcSEMS was inserted. One patient with a fcSEMS was later diagnosed with an extrahepatic cholangiocarcinoma but this was after CBD clearance had been achieved.

Conclusions The introduction of fcSEMS in a unit with cannulation rates and stone clearance rates above those mandated by the BSGE working group have resulted in very high stone extraction rate (95% by ITT and 100% by per protocol analysis). Only one adverse event was noted in this study which is felt unlikely to be related to fcSEMS insertion. We suggest larger studies should be conducted to further evaluate the efficacy and safety of FCSEMS for 'complex' stones together with a formal health economic analysis.

PTH-020 OUTCOMES OF ENDOSCOPIC STENTING FOR MALIGNANT DUODENAL OBSTRUCTION – EXPERIENCE OF A SINGLE CENTRE SERVICE

Priyan Odedra, Vishal Amin, George Goodchild*, Harry Martin, Gavin Johnson, Stephen Pereira, George Webster, Michael Chapman. *UCLH, London, UK*

10.1136/gutjnl-2019-BSGAbstracts.45

Introduction Duodenal obstruction may occur as a complication of duodenal, locally advanced or metastatic cancer. The resulting gastric outlet obstruction may reduce quality of life and life expectancy and the physiological milieu of malnutrition may interrupt palliative chemotherapy. We aim to evaluate of the technical and clinical outcomes of patients undergoing duodenal stent placement for malignant duodenal obstruction.

Methods Retrospective study of all patients referred for endoscopic duodenal stent placement from Jan 2014 - Jan 2018. Data was collected from endoscopy procedure records and electronic patient records. All patients with intent for duodenal stenting were included. Technical success was defined by endoscopic or radiographic evidence of satisfactory stent position. Outcome measures included removal of enteral tube (NG/NJ), cessation of vomiting, recommencement of oral nutrition, initiation or resumption of chemotherapy, complications and overall survival.

Results 50 patients were referred for duodenal stenting (F=31, median age 68 years). CT scans were available for all patients and all cases were reviewed within our specialist MDM. The level of the obstruction was D1 (26/50), D2 (17/50) and D3 (7/50). Aetiology of malignant obstruction was: pancreatic (n=15), gastric (n=7), ovarian (n=6), cholangiocarcinoma (n=5), duodenal (n=5), colorectal (n=3), breast (n=2) and hepatocellular (n=1). Stenting was attempted in 48 patients (2 were deemed unfit). Successful stent placement was achieved in 43/48 (90%) of patients, with a failure to stent the remaining 5 patients due to an inability to cross the stricture with a wire. A total of 51 uncovered, self-expanding 22 mm diameter metal stents were placed in 43 patients (1 patient required 2 stents at the index procedure, 6 patients required 1 further stent and 1 patient required 2 further stents). The median stent length was 9 cm (range 6–12 cm). Technical success rates were 90%. Clinical success rates were as follows: Subsequent removal of enteral tube post-procedure 68%, cessation of vomiting 64%, recommencement of oral diet 58%, further chemotherapy 29%. Overall 28 day survival was 85% and 6 month survival was 33% (median survival 66 days). There were no immediate complications following stent placement. 1 patient developed biliary sepsis 5 days post-stenting (previously normal LFTs) and died within 28 days. 3 patients developed obstructive jaundice following stenting (at 4 months, 8 months and 21 months), which was successfully treated with percutaneous stenting in all cases.

Conclusion Providing a guidewire can be passed across the stricture, duodenal stenting for malignancy has a high technical success rate in our centre. Early clinical benefit is seen in the majority of patients, and of the 41 patients alive at 3 months, only 3 (7%) required re-intervention during this period. At 6 months, 16 patients were alive, 7 of whom (44%) had required re-intervention. This single centre experience demonstrates high technical and clinical success rates for stenting in patients with malignant duodenal obstruction, with benefit maintained well beyond 3 months. In those patients that survived >6 months, half had further chemotherapy.

PTH-021 PROXIMALLY MIGRATED PANCREATIC STENTS – ENDOSCOPIC MANAGEMENT AND OUTCOME AT A TERTIARY CENTRE

¹George Goodchild*, ²Jonathan Potts, ¹Harry Martin, ²Douglas Thorburn, ¹Michael Chapman, ¹Gavin Johnson, ¹Stephen Pereira, ¹George Webster. ¹UCLH, London, UK; ²Royal Free Hospital, London, UK

10.1136/gutjnl-2019-BSGAbstracts.46

Introduction Pancreatic stents (PS) are increasingly used to aid biliary cannulation and reduce the risk of pancreatitis during endoscopic retrograde cholangiopancreatography (ERCP). Proximal PS migration is uncommon (reported in 2–5%) but poses a significant problem due to the risk of pancreatitis and pain.